The Solicitor General of the United States has filed an
amicus brief in Sandoz Inc. v. Amgen Inc., asking
the Supreme Court to grant certiorari and reverse the
Federal Circuit's interpretation of one of the "patent
dance" provisions of the biosimilar statute. In particular,
the Solicitor General does not agree that the pre-marketing notice
required by 21 USC § 262(l)(8)(A) cannot be given
until the biosimilar product has been approved by the FDA. While
not dispositive, this filing increases the odds that the Court will
weigh in on this issue, and may increase the odds that the Supreme
Court also will side with Sandoz.
The Neupogen® // Zarxio® Biosimilar Dispute
This case surrounds the first biosimilar product approved under
the Biologics Price Competition and Innovation Act
(BPCIA)–Sandoz' Zarxio® (filgrastim-sndz) product,
which was approved as a biosimilar of Amgen's Neupogen®
(filgrastim) product on March 6, 2015.